The NHS in England has just approved a groundbreaking daily pill for treating endometriosis, offering new hope to women who have been unable to find relief with existing options.
Endometriosis affects around one in ten women of reproductive age, causing painful symptoms and infertility, yet there is still no cure. Current treatments—such as painkillers, hormonal contraceptives, and surgery—are often inadequate or unsuitable for many patients.
A new daily pill, linzagolix, has now been approved by NICE for NHS use, offering a much-needed alternative. Clinical trials show it significantly reduces pain with fewer side effects than existing GnRH agonists. Linzagolix works by suppressing oestrogen and can reduce or stop menstrual bleeding, improving symptoms of endometriosis.
Preclinical studies in animals confirmed its safety, effectiveness, and mechanism of action. Beyond endometriosis, linzagolix has also been approved in the EU for uterine fibroids and shows potential for treating other hormone-dependent conditions like PCOS and BPH.
While not a cure, linzagolix could transform quality of life for many women and highlights the importance of investment in women’s health research, an area long underfunded and neglected.